Abviva Company Description
Abviva aims to bring better diagnostics to the fight against breast cancer. The drug developer (formerly known as Genesis Bioventures) is working on proteomics-based cancer diagnostics and therapeutics. Its wholly owned subsidiary Biomedical Diagnostics has developed a blood test, called the Mammastatin Serum Assay, which assesses a person's risk for developing breast cancer. Abviva also has a significant stake in Prion Developmental Laboratories, a developer of diagnostic tools for Mad Cow Disease and a similar neurodegenerative disorder that affects deer and elk called Chronic Wasting Disease.
View the Comprehensive Company Description for Abviva
The Company Description provides a historical perspective of Abviva's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Abviva's evolution in the marketplace.
